Business Context and Reporting Period
This Form 8-K filing by Supernus Pharmaceuticals, Inc. covers events occurring on January 10, 2018, and January 11, 2018. The report addresses the passing of independent director William A. Nuerge and the subsequent Board actions taken to maintain compliance with NASDAQ listing rules regarding Audit Committee composition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Director Departure: William A. Nuerge, an independent director since 2006 and member of the Audit and Compensation Committees, passed away on January 10, 2018.
- Listing Non-Compliance: Mr. Nuerge's death reduced the Audit Committee to two members, violating NASDAQ Rule 5605(c)(2), which requires a minimum of three members.
- Committee Appointments: On January 11, 2018, the Board appointed Georges Gemayel, Ph.D., to the Audit Committee and Fred Hudson to the Compensation Committee to fill the vacancies.
Outlook, Risks, and Management Commentary
Management expressed deep sadness regarding Mr. Nuerge's passing and extended condolences to his family. The Company notified NASDAQ on January 12, 2018, of the temporary non-compliance and the corrective actions taken to regain compliance. A press release announcing the passing was issued on January 12, 2018. No financial risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the current composition of the Audit and Compensation Committees to ensure continued NASDAQ compliance.
- Confirm the background and independence status of the newly appointed directors, Georges Gemayel, Ph.D., and Fred Hudson.
- Review the press release dated January 12, 2018 (Exhibit 99.1) for additional details regarding Mr. Nuerge's tenure and contributions.